Cite
CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
MLA
Pu, Ning, et al. “CD25 and TGF-β Blockade Based on Predictive Integrated Immune Ratio Inhibits Tumor Growth in Pancreatic Cancer.” Journal of Translational Medicine, vol. 16, no. 1, Oct. 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s12967-018-1673-6.
APA
Pu, N., Zhao, G., Yin, H., Li, J., Nuerxiati, A., Wang, D., Xu, X., Kuang, T., Jin, D., Lou, W., & Wu, W. (2018). CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Journal of Translational Medicine, 16(1), N.PAG. https://doi.org/10.1186/s12967-018-1673-6
Chicago
Pu, Ning, Guochao Zhao, Hanlin Yin, Jian-ang Li, Abulimiti Nuerxiati, Dansong Wang, Xuefeng Xu, et al. 2018. “CD25 and TGF-β Blockade Based on Predictive Integrated Immune Ratio Inhibits Tumor Growth in Pancreatic Cancer.” Journal of Translational Medicine 16 (1): N.PAG. doi:10.1186/s12967-018-1673-6.